An efficacy and safety study of vibegron add-on therapy in men with persistent storage symptoms receiving α-1 blockers or PDE5 inhibitor for benign prostatic hyperplasia and to determine the factors affecting the efficacy of vibegron
Latest Information Update: 01 Feb 2021
At a glance
- Drugs Vibegron (Primary) ; Naftopidil; Silodosin; Tadalafil; Tamsulosin
- Indications Overactive bladder
- Focus Therapeutic Use
- 01 Feb 2021 New trial record
- 20 Jan 2021 Primary endpoint (change in total OABSS from baseline to end of treatment at 12 weeks) has been met.
- 20 Jan 2021 Results published in the Urology.